ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Health Services Research"

  • Abstract Number: 0808 • ACR Convergence 2023

    Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System

    Bryant England1, Tate Johnson1, Yangyuna Yang1, Punyasha Roul1, Daniel Hershberger1, Brian Sauer2, Grant Cannon3, Joshua Baker4 and Ted R Mikuls5, 1University of Nebraska Medical Center, Omaha, NE, 2Salt Lake City VA/University of Utah, Salt Lake City, UT, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4University of Pennsylvania, Philadelphia, PA, 5Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
  • Abstract Number: 1617 • ACR Convergence 2023

    Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022

    Eric Roberts1, Jing Li1, Nick Bansback2, Chien-Wen Tseng3, Steve Shiboski1, Gabriela Schmajuk4 and Jinoos Yazdany1, 1University of California San Francisco, San Francisco, CA, 2University of British Columbia, Vancouver, BC, Canada, 3University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, 4UCSF / SFVA, San Francisco, CA

    Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)).…
  • Abstract Number: 1860 • ACR Convergence 2023

    Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis

    Alyssa Howren1, Eric Sayre2, J. Antonio Avina-Zubieta3, Joseph Puyat1, Deborah Da Costa4, Hui Xie5, Amit Gupta1 and Mary De Vera1, 1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Centre on Substance Use, Vancouver, BC, Canada, 3Arthritis Research Canada, Vancouver, BC, Canada, 4McGill University, Pointe-Claire, QC, Canada, 5Simon Fraser University, Richmond, BC, Canada

    Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
  • Abstract Number: 0170 • ACR Convergence 2023

    Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group)

    Lisa Traboco1, Pavel Ovseiko2, Sarah Dyball3, Tayyeba Khursheed4, ALEJANDRA BABINI5, Asgar Ali Kalla6, Catherine Hill7, Debashish Danda8, Dzifa Dey9, Elena Nikiphorou10, Ghita Harifi11, Ho SO12, Humeira Badshah13, Ihsane Hmamouchi14, Joan Marie Von Feldt15, Júlia Boechat Farani16, Mariana Peixoto Guimarães17, Kanon Jatuworapruk18, Laura Andreoli19, Nelly Ziade20, PENELOPE PALOMINOS21, Qian Wang22, Ran Nakashima23, Syed Haq24, Wilson Bautista-Molano25, Yoshiya Tanaka26, Grace Wright27, Vikas Agarwal28, Laura Coates29 and Latika Gupta30, 1University of the Philippines - Manila, St Luke's Medical Center - Bonifacio Global City, Paranaque, Manila, Philippines, 2Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom, 3University of Manchester, Stockport, United Kingdom, 4Pakistan institute of Medical Sciences, Islamabad, Pakistan, 5Hospital Italiano Cordoba, Cordoba, Argentina, 6Department of Medicine, University of Cape Town, Cape Town, South Africa, 7The Queen Elizabeth Hospital, Woodville, Australia, 8Christian Medical College & Hospital, Vellore, India, 9University of Ghana Medical School, Rheumatology Unit Department of Medicine and Therapeutics, Korle bu Teaching Hospital, Accra, Ghana, 10King's College London, London, United Kingdom, 11HBMC, Dubai, United Arab Emirates, 12The Chinese University of Hong Kong, Hong Kong, China, 13Dr Humeira Badsha Medical Center, Dubai, United Arab Emirates, Dubai, United Arab Emirates, 14Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco, 15University of Pennsylvania, Pennsylvania, PA, 16Division of Rheumatology, Hospital Santa Casa de Misericórdia de Juiz de Fora, Juiz de Fora, Brazil, 17Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, MG, Brazil, 18Thammasat University, Pathumthani, Thailand, 19University of Brescia, Brescia, Italy, 20Saint-Joseph University, Beirut, Lebanon, 21Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 22Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences (CAMS), Peking Union Medical College Hospital, The Ministry of Education Key Laboratory, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, 23Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 24BSM Medical University, Dhaka, Bangladesh, 25University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, 26University of Occupational and Environmental Health, Kitakyushu, Japan, 27Grace C Wright MD PC, New York, NY, 28Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 29University of Oxford, Oxford, United Kingdom, 30Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom

    Background/Purpose: There is growing attention to gender inequity within rheumatology with persistent challenges in achieving pay parity, career progression, & access to leadership roles. In…
  • Abstract Number: 0996 • ACR Convergence 2023

    Will Patients Engage with Digital Technologies as Part of Routine Healthcare?

    Jeffrey R Curtis1, Sandeep Sodhi2, Yuji Su3, Scott Laster4, Fenglong Xie2, Ye Liu5 and Corey Patrick4, 1Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 2Illumination Health, Hoover, AL, 3University of Alabama at Birmingham and Illumination Health, Birmingham, AL, 4Micare, Memphis, TN, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via…
  • Abstract Number: 1618 • ACR Convergence 2023

    Intervention to Improve Medication Adherence Among Patients with SLE

    Kai Sun1, Nneka Molokwu1, Emily Hanlen1, Amy Corneli2, Kathryn Pollak1, Jennifer Rogers1, Rebecca Sadun1, Lisa Criscione-Schreiber2, Jayanth Doss1, Hayden Bosworth1 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Chapel Hill, NC

    Background/Purpose: Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. To optimize medication adherence and SLE outcomes, we…
  • Abstract Number: 1908 • ACR Convergence 2023

    Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center

    Kubra Bugdayli1, Amber Meyer1, Antoinette Keith1, Karunakar Dirisala1, Guillermo Quiceno1 and Puneet Bajaj2, 1University of Texas Southwestern Medical Center, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX

    Background/Purpose: Hypertension is the most common modifiable risk factor for cardiovascular diseases among all adults. Studies have shown that single blood pressure (BP) measurements vary…
  • Abstract Number: 0171 • ACR Convergence 2023

    A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

    Vibeke Strand1, Prajakta Masurkar2, Jennifer Reckleff3, Taylor Schwartz4, Alison Silverstein4, Jennifer Osborne4, Josie Lloyd4, Brian Leinwand4, Elaine Karis5, Fatima Barbar-Smiley6 and Karen Costenbader7, 1Stanford University, Portola Valley, CA, 2Amgen, Inc., Atlanta, GA, 3Amgen, Inc., Westlake Village, CA, 4Inovalon Insights, Bowie, MD, 5Amgen, Inc., Colts Neck, NJ, 6Amgen, Inc., Dublin, OH, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
  • Abstract Number: 0997 • ACR Convergence 2023

    Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus

    W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI

    Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
  • Abstract Number: 1619 • ACR Convergence 2023

    Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis

    Carolyn Thorpe, Ryan Hickson, Sherrie Aspinall, Vimal Derebail, Xinhua Zhao, Joshua Thorpe, Binxin Cao, Alexa Ehlert, Ronald Falk and Susan Hogan, University of North Carolina, Chapel Hill, NC

    Background/Purpose: Infections are the leading cause of hospitalization and mortality in patients with ANCA vasculitis (AV). Multiple AV treatment guidelines recommend antimicrobial prophylaxis during treatment…
  • Abstract Number: 2002 • ACR Convergence 2023

    Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Yamei Wang4, Leny Pearman4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Boston, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
  • Abstract Number: 0172 • ACR Convergence 2023

    Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review

    Krystel Aouad1, Maarten de Wit2, Muriel Elhai3, Diego Benavent4, Heidi Bertheussen5, Jette Primdahl6, Codruta Zabalan7, Paul Studenic8 and Laure Gossec9, 1Saint George Hospital University Medical Center, Beirut, Lebanon, 2Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, 3University Hospital zurich, University of Zurich, Zurich, Switzerland, 4Hospital la Paz, Madrid, Spain, 5Patient Research Partner, Oslo, Norway, 6University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, 7Patient Research Partner, Romania, Romania, Romania, 8Medical University of Vienna and Karolinska Institutet (sweden), Vienna, Austria, 9Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

    Background/Purpose: Patient research partners (PRPs) participate in research teams and provide unique and valuable input. Their integration as equal partners is recommended (1). However, PRP…
  • Abstract Number: 0998 • ACR Convergence 2023

    Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives

    Rebecca Slotkin1, Daniel Granda Calderón2, Joselito Malca Hernandez2, Diego Cabrera3, Carlos Manuel Benites Villafane4, Patricia Jannet García5 and Evelyn Hsieh6, 1Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health, New Haven, CT, 2Facultad de Medicina Alberto Hurtado de la Universidad Peruana Cayetano Heredia, Lima, Peru, 3Yale University, Department of Medicine, Section of Rheumatology; Department of Internal Medicine, Waterbury Hospital, New Haven, CT, 4Ministerio de Salud, Peru, Lima, Peru, 5Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru, 6Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT

    Background/Purpose: Persons living with HIV (PLWH) have a higher risk of developing age-related non-communicable diseases (NCDs), such as osteoporosis and sarcopenia. In Peru, HIV providers…
  • Abstract Number: 1656 • ACR Convergence 2023

    Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI)

    anna Fryxelius1, Amy Martinsen2, Ida Løchting3, Linda Aimee Hartford Kvæl4, Astrid Lunestad2, Astrid Bergland4 and Kjersti Storheim2, 1Norwegian Rheumatism Association / REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, 2Oslo University Hospital, Oslo, Norway, 3REMEDY - Center for Treatment of Rheumatic and Musculoskeletal Diseases, Oslo, Norway, 4OsloMET, Oslo, Norway

    Background/Purpose: Patient and public involvement (PPI) is gaining increasing recognition as important to ensure research is relevant and to reduce avoidable research waste. Active collaboration…
  • Abstract Number: 2023 • ACR Convergence 2023

    Transition Readiness over Time in a Rheumatology Transition Clinic

    Background/Purpose: In 2018 we designed a Rheumatology Transition clinic to care for adolescent patients with autoimmune disease. We incorporate Health Care Transition curriculum (HCT) into…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology